At what enterprise value was PSV GROUP acquired in 2024?

You can find the full valuation details of PSV GROUP on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PSV GROUP when it was acquired by L-GAM / CAPZA / IDIA CAPITAL INVESTISSEMENT?

The exact EV/EBITDA multiple for PSV GROUP is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

What was the revenue of PSV GROUP at the time of the deal?

The revenue of PSV GROUP at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of PSV GROUP during the acquisition?

PSV GROUP's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PSV GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PSV GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ca-idia.com/wp-content/uploads/2024/09/CP-IDIA_CI-PSV.pdf

← DATABASE

Home Database Healthcare & PharmaPSV GROUP

06/2024

PSV GROUP acquired by L-GAM, CAPZA & IDIA CAPITAL INVESTISSEMENT

FRANCE Health Providers / Outpatient Care / Radiology REV 50M - 100M EUR

Context

L-GAM, CAPZA, IDIA Capital Investissement, and Bpifrance are acquiring a minority stake in PSV Group from its associate physicians. The transaction allows for the entry of a consortium of minority financial partners while ensuring that the associate doctors, who remain majority shareholders, retain full operational and strategic control of the group. This strategic partnership is designed to provide the financial resources and complementary expertise required to support an ambitious new development phase. Specifically, the investment will fund the construction of a new specialized center in Lens while allowing the group to accelerate its medical project and advance its sustainable development goals. The operation focuses on maintaining the group's long-term independence and ensuring medical excellence in cancer care for the regional population.

PSV GROUP, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1950, the Pole d'Imagerie et de Cancerologie du Pont Saint-Vaast is a leading oncology and medical imaging group based in the Hauts-de-France region. It operates a network of seven specialized centers across the Douai, Lens, and Lille areas, serving a population of over three million inhabitants. The group provides an integrated patient pathway, combining advanced diagnostics through medical imaging and nuclear medicine with a full range of non-surgical cancer treatments, including radiotherapy, brachytherapy, and chemotherapy. Equipped with high-end technology, the organization manages ten linear accelerators, including a specialized robotic radiosurgery system. Led by a medical executive committee of nearly fifty doctors, the group employs approximately 190 people and is dedicated to clinical excellence and innovation in cancer care within its regional territory.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
10/2024	QUALIUM	IMPC (IMAGERIE MEDICALE PARIS CENTRE)	FRANCE	Radiology
08/2024	ORLANDO HEALTH	BROOKWOOD BAPTIST HEALTH SERVICES	UNITED STATES	Clinics / Hospitals
06/2024	INTEGRAL DIAGNOSTICS LIMITED	CAPITOL HEALTH LIMITED	AUSTRALIA	Radiology
01/2024	ARDIAN / BPIFRANCE / MACSF	APRIUM PHARMACIE	FRANCE	Pharmacy
12/2023	ANDERA PARTNERS	GROUPE IMAGERIE CARDINET	FRANCE	Radiology
12/2023	ESSLING CAPITAL	X-RAY PHOCEA	FRANCE	Radiology
10/2023	EQT PARTNERS	VETPARTNERS	AUSTRALIA	Vet Clinics
08/2023	QUADRIVIO GROUP	THE PRIVATE CLINIC (TPC)	UNITED KINGDOM	Aesthetic & Cosmetic Clinics
08/2023	BAIN CAPITAL	ESTIA HEALTH	AUSTRALIA	Nursing Homes
07/2023	MEDIAN KLINIKEN	HESTIA ALLIANCE	SPAIN	Clinics / Hospitals

REFERENCES

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PSV GROUP by L-GAM / CAPZA / IDIA CAPITAL INVESTISSEMENT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: capza / idia capital investissement / l-gam